Written by The Geographic Atrophy Treatment Market is expanding as the aging population and growing prevalence of age-related macular degeneration increase demand for therapies addressing geographic atrophy (GA), an advanced form of dry age-related macular degeneration associated with progressive loss of retinal cells and vision. Geographic atrophy can cause gradual and irreversible deterioration of central or peripheral vision, creating significant demand for early diagnosis, disease monitoring, and treatments designed to slow progression. Advances in retinal imaging and increasing awareness of age-related eye diseases are supporting development of this specialized market.
The treatment landscape has evolved with the introduction of complement-inhibiting therapies designed to slow the progression of geographic atrophy. Pegcetacoplan and avacincaptad pegol are complement pathway inhibitors approved in the United States for geographic atrophy associated with age-related macular degeneration. These treatments are administered through intravitreal injection and are intended to reduce the rate of geographic-atrophy lesion growth rather than restore already lost retinal tissue. Ongoing research is evaluating additional complement-targeted approaches, gene therapies, sustained-delivery technologies, and other potential treatment strategies that could expand options for patients.
Regional market development is influenced by the aging demographic, ophthalmology infrastructure, availability of retinal specialists, diagnostic capabilities, reimbursement conditions, and access to newly approved therapies. North America has been an important market because of its established ophthalmic healthcare infrastructure and availability of advanced retinal treatments, while Europe and Asia-Pacific provide additional opportunities as diagnosis and access to specialized eye care increase. Continued research into complement inhibition, earlier disease detection, retinal imaging, and longer-acting treatment delivery systems is expected to shape the future development of the geographic atrophy treatment market.